#ASCO26: New Data Released for VEGF Bispecifics From BioNTech-BMS, Pfizer-3SBio

Why It Matters

The data suggest that VEGF bispecifics could soon challenge existing anti‑angiogenic standards, reshaping treatment algorithms and attracting significant investment ahead of potential FDA filings.

Key Takeaways

• BioNTech‑BMS VEGF bispecific shows 45% ORR in Phase 1/2 trial
• Pfizer‑3SBio combo achieves disease control in 78% of patients
• Safety profile comparable to existing anti‑VEGF monotherapies
• Data intensifies competition ahead of market entry for ivonescimab

Pulse Analysis

The ASCO unveiling of VEGF bispecific antibodies from BioNTech‑BMS and Pfizer‑3SBio underscores a broader shift toward multi‑targeted immuno‑oncology. By simultaneously binding VEGF and a tumor‑associated antigen, these agents aim to inhibit angiogenesis while delivering a focused immune attack. This dual‑action design addresses the limitations of traditional anti‑VEGF drugs, which often suffer from resistance and modest durability, positioning bispecifics as a next‑generation therapeutic class.

Clinical read‑outs from the early‑stage trials are encouraging. BioNTech‑BMS reported a 45% overall response rate in a heavily pre‑treated solid‑tumor population, a figure that rivals or exceeds many approved checkpoint inhibitors in comparable lines of therapy. Pfizer‑3SBio’s candidate achieved disease control in 78% of patients, with median progression‑free survival extending beyond six months. Importantly, both programs maintained safety profiles similar to existing anti‑VEGF agents, suggesting that the added targeting does not exacerbate vascular toxicity—a key concern for clinicians.

The competitive landscape is heating up as Summit Therapeutics and Akeso prepare to launch ivonescimab, a bispecific that also targets VEGF. The new data intensify market dynamics, prompting investors to reassess pipeline valuations and potential partnership opportunities. If the promising early results translate into Phase 3 success, regulators could see a wave of submissions within the next two years, accelerating the entry of bispecifics into the oncology market and potentially redefining standard of care for angiogenesis‑driven cancers.